Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 6fludarabine 4Magnetic Resonance Spectroscopy 3Flow Cytometry 3trametinib 2pembrolizumab 2liposomal doxorubicin 2dabrafenib 2aldesleukin 2Specimen Handling 2Methylprednisolone 2Immunologic Techniques 2Gemcitabine 2Dexamethasone 2Biopsy 2Azacitidine 2Alemtuzumab 2ulixertinib 1trastuzumab biosimilar HLX02 1sargramostim 1saracatinib 1sapanisertib 1ruxolitinib 1rucaparib 1resiquimod 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × saracatinib × Plasma cell × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡